Abnormal dreams and night terrors with atogepant: A case series.
American Journal of Health-System Pharmacy July 13, 2026 Jason To, Heather Cournoyer, Amanda G. Kennedy et al.
PURPOSE To describe a potential emerging neuropsychiatric adverse effect, abnormal dreams or night terrors, associated with atogepant (a calcitonin gene-related peptide receptor antagonist) observed in 4 patients treated at a tertiary headache clinic, and to place these observations in the context of existing postmarketing pharmacovigilance signals. SUMMARY Four patients with migraine developed...